Bio-product Molecule Design
and Optimization Platform

Molecule Design Molecule Optimization

Introduction

The AlfaDAX system enables customers to quickly screen and modify protein candidates before they enter the CMC stage, reducing trial and error costs and accelerating the development of new drugs.

Advantages

  • 5 mins
  • 5 mins

    Assessment report

  • 5 days
  • 5 days

    Optimization report

  • Optimized 3 to 1 package
  • Optimized 3 to 1 package

    (Humanization +Affinity +
    Developability)

  • <i>in silico</i> work
  • in silico work

    instead of wet lab work

    Molecule Design

    ● High-Fidelity Predictions: 100% consistency between in silico results and experimental validation.

    Monoclonal Antibody Affnity Increased 29-Fold

  • ● High-Fidelity Predictions: 100% consistency between in silico results and experimental validation.
  • ● Structure-Activity Relationship: Deep insights into the correlation between molecular conformation and bioactivity.

    Relationship Between Conformation and Activity

  • ● Structure-Activity Relationship: Deep insights into the correlation between molecular conformation and bioactivity.
  • Molecule Optimization

    Affinity Enhancement

    ● Case 1

    Monoclonal antibody with 29-fold affinity enhancement.

  • ● Case 1
  • ● Case 2

    Multi-metric validation achieving 43-fold affinity improvement.

  • ● Case 2
  • ● Case 3

    Nanobody optimization with 19.6-fold affinity enhancement.

  • ● Case 3
  • Humanization Enhancement

    ● Case 1

    Triple optimization for monoclonal antibody humanization.

  • ● Case 1
  • ● Case 2

    Breakthrough in humanization of challenging monoclonal antibodies.

  • ● Case 2
  • ● Case 3

    Nanobody humanization with comprehensive performance enhancement.

  • 3-in-1: Affinity + Humanization + Developability

    ● Case 1

    77-fold affinity improvement with concurrent functional and stability enhancement.

  • ● Case 1
  • ● Case 2

    Simultaneous optimization of affinity and humanization (94.32% germline identity).

  • ● Case 2
  • ● Case 3

    Multidimensional optimization of bispecific antibodies for significant potency gains.

  • ● Case 3
  • Get started with a trial

    Get the Scheme

  • Schedule a Meeting

    I agree to the privacy policy.

    Submit
    Global Bioprocessing Made Simpler and More Efficient